An Open Label, Multicenter Trial Assessing the Acceptability of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Patients With Type 2 Diabetes and Dyslipidemia
Phase of Trial: Phase III
Latest Information Update: 27 Jun 2012
At a glance
- Drugs Fenofibrate/metformin (Primary)
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; Solvay Pharmaceuticals
- 20 Apr 2010 Actual patient number (29) added as reported by ClinicalTrials.gov.
- 31 Aug 2007 Status changed from in progress to completed.
- 03 Jul 2007 New trial record.